QuidelOrtho Co. (NASDAQ:QDEL) Shares Bought by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC grew its stake in QuidelOrtho Co. (NASDAQ:QDEL) by 14.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,985 shares of the company’s stock after purchasing an additional 1,289 shares during the quarter. Mutual of America Capital Management LLC’s holdings in QuidelOrtho were worth $445,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Proficio Capital Partners LLC acquired a new stake in QuidelOrtho in the 4th quarter worth about $871,000. Oregon Public Employees Retirement Fund lifted its position in shares of QuidelOrtho by 13.9% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 15,528 shares of the company’s stock valued at $692,000 after acquiring an additional 1,900 shares in the last quarter. Amalgamated Bank boosted its stake in shares of QuidelOrtho by 11.3% in the fourth quarter. Amalgamated Bank now owns 19,911 shares of the company’s stock worth $887,000 after acquiring an additional 2,014 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of QuidelOrtho during the fourth quarter worth approximately $602,000. Finally, Handelsbanken Fonder AB raised its stake in QuidelOrtho by 13.5% in the 4th quarter. Handelsbanken Fonder AB now owns 16,819 shares of the company’s stock valued at $749,000 after purchasing an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

Insider Activity at QuidelOrtho

In other QuidelOrtho news, CEO Brian J. Blaser bought 6,033 shares of QuidelOrtho stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average cost of $41.42 per share, with a total value of $249,886.86. Following the completion of the acquisition, the chief executive officer now owns 6,033 shares of the company’s stock, valued at approximately $249,886.86. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.00% of the stock is owned by corporate insiders.

QuidelOrtho Price Performance

QuidelOrtho stock opened at $40.80 on Monday. The stock has a market cap of $2.75 billion, a P/E ratio of -1.35 and a beta of 0.10. The company has a current ratio of 1.22, a quick ratio of 0.69 and a debt-to-equity ratio of 0.71. The company has a fifty day simple moving average of $42.69 and a 200-day simple moving average of $42.19. QuidelOrtho Co. has a 12-month low of $29.74 and a 12-month high of $49.45.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. Equities analysts expect that QuidelOrtho Co. will post 2.3 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on QDEL shares. StockNews.com cut shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. William Blair reissued a “market perform” rating on shares of QuidelOrtho in a research report on Wednesday, November 20th. Royal Bank of Canada decreased their price objective on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating on the stock in a report on Thursday, February 13th. UBS Group boosted their price target on shares of QuidelOrtho from $43.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday, February 13th. Finally, Jefferies Financial Group began coverage on shares of QuidelOrtho in a research note on Tuesday, December 10th. They set a “hold” rating and a $43.00 target price on the stock. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $51.20.

QuidelOrtho Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.